HRP20100434T1 - Postupci liječenja zaraze virusom hiv - Google Patents

Postupci liječenja zaraze virusom hiv Download PDF

Info

Publication number
HRP20100434T1
HRP20100434T1 HR20100434T HRP20100434T HRP20100434T1 HR P20100434 T1 HRP20100434 T1 HR P20100434T1 HR 20100434 T HR20100434 T HR 20100434T HR P20100434 T HRP20100434 T HR P20100434T HR P20100434 T1 HRP20100434 T1 HR P20100434T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
agent
treatment
Prior art date
Application number
HR20100434T
Other languages
English (en)
Croatian (hr)
Inventor
Lin Pin-Fang
Nowicka-Sans Beata
Yamanaka Gregory
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100434(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20100434T1 publication Critical patent/HRP20100434T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20100434T 2004-03-24 2005-03-01 Postupci liječenja zaraze virusom hiv HRP20100434T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
HRP20100434T1 true HRP20100434T1 (hr) 2010-09-30

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100434T HRP20100434T1 (hr) 2004-03-24 2005-03-01 Postupci liječenja zaraze virusom hiv

Country Status (30)

Country Link
US (1) US7776863B2 (show.php)
EP (1) EP1732604B1 (show.php)
JP (1) JP4847441B2 (show.php)
KR (1) KR101158140B1 (show.php)
CN (1) CN1956720B (show.php)
AR (1) AR048333A1 (show.php)
AT (1) ATE474602T1 (show.php)
AU (1) AU2005235116B2 (show.php)
BR (1) BRPI0509140A (show.php)
CA (1) CA2561146C (show.php)
CY (1) CY1111613T1 (show.php)
DE (1) DE602005022420D1 (show.php)
DK (1) DK1732604T3 (show.php)
ES (1) ES2347801T3 (show.php)
GE (1) GEP20104925B (show.php)
HR (1) HRP20100434T1 (show.php)
IL (1) IL178141A (show.php)
IN (1) IN2012DN06436A (show.php)
MY (1) MY144318A (show.php)
NO (1) NO337116B1 (show.php)
NZ (1) NZ549778A (show.php)
PE (1) PE20060148A1 (show.php)
PL (1) PL1732604T3 (show.php)
PT (1) PT1732604E (show.php)
RU (1) RU2367439C2 (show.php)
SI (1) SI1732604T1 (show.php)
TW (1) TWI347184B (show.php)
UA (1) UA88463C2 (show.php)
WO (1) WO2005102392A2 (show.php)
ZA (1) ZA200607959B (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
SG191841A1 (en) 2011-01-31 2013-08-30 Bristol Myers Squibb Co Methods of making hiv attachment inhibitor prodrug compound and intermediates
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281960T3 (es) * 1998-03-02 2007-10-01 The University Of North Carolina At Chapel Hill Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso.
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
BR0214842A (pt) * 2001-12-12 2005-01-11 Bristol Myers Squibb Co Inibidores de integrase hiv
BRPI0215050B8 (pt) * 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem

Also Published As

Publication number Publication date
JP4847441B2 (ja) 2011-12-28
ZA200607959B (en) 2008-06-25
KR101158140B1 (ko) 2012-06-19
WO2005102392A2 (en) 2005-11-03
RU2006137555A (ru) 2008-04-27
CY1111613T1 (el) 2015-10-07
PE20060148A1 (es) 2006-03-04
CN1956720A (zh) 2007-05-02
NO20064547L (no) 2006-10-06
GEP20104925B (en) 2010-03-25
ES2347801T3 (es) 2010-11-04
DE602005022420D1 (de) 2010-09-02
WO2005102392A3 (en) 2006-07-20
RU2367439C2 (ru) 2009-09-20
NZ549778A (en) 2010-09-30
TW200538117A (en) 2005-12-01
IL178141A (en) 2010-11-30
US20050215545A1 (en) 2005-09-29
AR048333A1 (es) 2006-04-19
CA2561146A1 (en) 2005-11-03
DK1732604T3 (da) 2010-11-15
AU2005235116A1 (en) 2005-11-03
JP2007530540A (ja) 2007-11-01
MY144318A (en) 2011-08-29
IN2012DN06436A (show.php) 2015-10-09
SI1732604T1 (sl) 2010-10-29
PT1732604E (pt) 2010-09-24
US7776863B2 (en) 2010-08-17
KR20070011322A (ko) 2007-01-24
PL1732604T3 (pl) 2010-12-31
ATE474602T1 (de) 2010-08-15
AU2005235116B2 (en) 2011-03-31
CN1956720B (zh) 2010-12-15
NO337116B1 (no) 2016-01-25
BRPI0509140A (pt) 2007-09-04
EP1732604B1 (en) 2010-07-21
IL178141A0 (en) 2006-12-31
EP1732604A2 (en) 2006-12-20
UA88463C2 (ru) 2009-10-26
TWI347184B (en) 2011-08-21
HK1096540A1 (en) 2007-06-01
CA2561146C (en) 2013-12-24

Similar Documents

Publication Publication Date Title
HRP20100434T1 (hr) Postupci liječenja zaraze virusom hiv
BRPI0519471A2 (pt) formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo
SI1509521T1 (sl) 1H-imidazo(4,5-C)kinolinski derivati za zdravljenje od protein kinaze odvisnih bolezni
TN2018000335A1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
JP2007530540A5 (show.php)
JP2012236857A5 (show.php)
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
CN113727715A (zh) 用伐昔洛韦和泛昔洛韦的组合治疗单纯疱疹
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
AR048324A1 (es) Metodos para tratar infecciones por vih
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
EP4516318A3 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
WO2007124358A3 (en) Pharmaceutical formulations for iontophoretic drug delivery
RU2015124954A (ru) Фармацевтические комбинации
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica